Sonoma Biotherapeutics is excited to announce a significant funding milestone, having successfully raised $45 million in its latest financing round. Based in South San Francisco and Seattle, Sonoma is at the forefront of developing innovative engineered regulatory T cell (Treg) therapies aimed at tackling serious autoimmune and inflammatory conditions caused by imbalances within the immune system. Founded by leaders in Treg biology and cell therapy, the company leverages its proprietary platform technologies to pioneer a new generation of targeted Treg cell therapies. The primary purpose of this latest funding is to accelerate the development of these cutting-edge therapies, with the goal of inducing durable immune tolerance to treat and prevent a wide array of autoimmune disorders. This infusion of capital will enable Sonoma Biotherapeutics to further advance its clinical programs, enhance its research capabilities, and expand its team of experts who are dedicated to revolutionizing patient care in the realm of autoimmune and inflammatory diseases. With the ongoing support of our investors, we are poised to make significant strides in transforming Treg cell therapy from a concept into a holistic treatment option that can offer lasting relief for patients affected by debilitating immune-related conditions. The journey ahead is filled with promise, and we are eager to translate this investment into tangible advancements in the biotherapeutics landscape. Together, we envision a future where patients can live free from the burdens of autoimmune diseases, thanks to the groundbreaking work being done at Sonoma Biotherapeutics.
Revolutionizing Autoimmune Treatments: Sonoma Biotherapeutics Secures $45 Million in Funding
Get the full Sonoma Biotherapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx is also developing INF904, an orally administered, small molecule inhibitor of the C5a receptor. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com
$150.0M Unknown
today
Lunar Outpost
Lunar Outpost is the industry leader in commercial space robotics, lunar surface mobility, and in-space infrastructure. We are on a mission to enable an extended human presence in space while utilizing the vast resources in space to drive positive impacts here on Earth. From our five rovers headed to the Moon to explore, prospect, and establish infrastructure, to the creation of oxygen on Mars, our impact spans the solar system. Lunar Outpost’s mobility and robotic systems, ranging from our exploration-class Mobile Autonomous Prospecting Platform (MAPP) rover to our truck-sized industrial Lunar Terrain Vehicle (LTV), will be the workforce for the New Space economy and enable Lunar Outpost to bring the infinite value of space to benefit humanity on Earth and beyond. Through notable commercialization and amazing partnerships, Lunar Outpost creates tremendous value in the New Space economy. Lunar Outpost leads the Lunar Dawn team, consisting of General Motors, Goodyear, and MDA Space – the leading consortium for LTV providing mobility for Artemis astronauts, a critical component of the broader Artemis campaign that will enable a sustainable presence on the Moon. Lunar Outpost’s five upcoming lunar surface missions will make history, with our first rover set to be the first commercial rover on the Moon and the first rover in history to explore the lunar South Pole, while enabling the first sale of space resources in human history alongside many other firsts. Each of our next four rover voyages build on our capabilities and technology, all leading towards mobility and robotic systems that can reliably operate in the most extreme environments our solar system has to offer.
$30.0M Series b
today
Darkhive
Darkhive develops US-produced open autonomous robotics systems for the defense and public safety communities.
$30.0M Series b
today
Founders First Capital Partners
National lender serving BIPOC, veteran, LGBTQ+, & women-owned businesses, as well as businesses in LMI zones & those committed to diverse hiring practices. Helping accelerate business growth through our Revenue-Based Funding products & Advisory Services. Together, we can create more jobs, increase your revenues and bottom line, and provide more growth capital to help your business. We’re backed by the nation’s top philanthropic organizations, so that we can fund you with the right capital.
$3.9M Unknown
today
Nelson
We help companies reduce their carbon footprints, control their mobility costs and use energy more efficiently. Our data-driven software enables companies to plan, deploy and operate a successful electrification strategy for their car fleet. Nelson combines companies' fleet data and the charging ecosystem data to provide personalized recommendations -in real time & automatically.
$3.5M Seed
today